227626-60-0 Usage
Description
[1-(TERT-BUTOXYCARBONYLAMINO-METHYL)-CYCLOHEXYL]-ACETIC ACID is a complex organic compound with a unique molecular structure that features a cyclohexyl ring and a carboxylic acid group. [1-(TERT-BUTOXYCARBONYLAMINO-METHYL)-CYCLOHEXYL]-ACETIC ACID is characterized by its white powder form and is structurally related to amino acids, which may contribute to its potential applications in various industries.
Uses
Used in Pharmaceutical Industry:
[1-(TERT-BUTOXYCARBONYLAMINO-METHYL)-CYCLOHEXYL]-ACETIC ACID is used as a protected form of Gabapentin (G117250) for its ability to cross the blood-brain barrier. It serves as an anticonvulsant, which is essential in treating various neurological conditions such as epilepsy and neuropathic pain. The compound's structural similarity to γ-Aminobutyric Acid (GABA) allows it to interact with the GABAergic system, potentially enhancing its therapeutic effects.
Used in Chemical Synthesis:
Due to its unique molecular structure, [1-(TERT-BUTOXYCARBONYLAMINO-METHYL)-CYCLOHEXYL]-ACETIC ACID can be utilized as an intermediate in the synthesis of various pharmaceuticals, agrochemicals, and other specialty chemicals. Its reactivity and functional groups can be exploited to create a wide range of derivatives with diverse applications.
Used in Research and Development:
The compound's structural features and potential applications make it a valuable tool for researchers in the fields of medicinal chemistry, drug discovery, and materials science. It can be used to study the interactions between molecules and biological targets, as well as to develop new methodologies for the synthesis of complex organic molecules.
Check Digit Verification of cas no
The CAS Registry Mumber 227626-60-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,2,7,6,2 and 6 respectively; the second part has 2 digits, 6 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 227626-60:
(8*2)+(7*2)+(6*7)+(5*6)+(4*2)+(3*6)+(2*6)+(1*0)=140
140 % 10 = 0
So 227626-60-0 is a valid CAS Registry Number.
InChI:InChI=1/C14H25NO4/c1-13(2,3)19-12(18)15-10-14(9-11(16)17)7-5-4-6-8-14/h4-10H2,1-3H3,(H,15,18)(H,16,17)
227626-60-0Relevant articles and documents
Structural and morphological diversity of self-assembled synthetic γ-amino acid containing peptides
Konda, Maruthi,Kauffmann, Brice,Rasale, Dnyaneshwar B.,Das, Apurba K.
, p. 4089 - 4102 (2016)
Regulating the nanostructural morphology of synthetic hybrid peptides through external stimuli is still a great challenge. Here, we report the synthesis of constrained amino acid building block gabapentin (Gpn) based hybrid peptides and their structural a
Novel cilengitide-based cyclic RGD peptides as αvβ3 integrin inhibitors
Dangi, Abha,Marelli, Udaya Kiran,Meena, Chhuttan L.,Reichart, Florian,Sanjayan, Gangadhar J.,Singh, Dharmendra,Zahler, Stefan,Weinmüller, Michael
supporting information, (2020/02/28)
In this letter, we report a series of five new RGD-containing cyclic peptides as potent inhibitors to αvβ3 integrin protein. We have incorporated various unnatural lipophilic amino acids into the cyclic RGD framework of cilengitide, which is selective for αvβ3 integrin. All the newly synthesized cyclic peptides were evaluated in vitro solid phase binding assay and investigated for their binding behaviour towards integrin subtypes. All the cyclic peptides were synthesized in excellent yield following solution-phase coupling strategy. The cyclic RGD peptides 1a-e exhibited IC50 of 9.9, 5.5, 72, 11 and 3.3 nM, respectively, towards αvβ3 integrin protein. This finding offers further opportunities for the introduction unusual amino acids into the cyclic peptide framework of cilengitide.
SUBSTITUTED TRIAZOLES AND METHODS RELATING THERETO
-
Page/Page column 40, (2016/08/23)
Substituted 1,2,3-triazole compounds are disclosed which have utility in the treatment of a variety of neurological disorders. The compounds provided herein have the general structure wherein R1, R2, R3 and n are as defined herein, including stereoisomers, esters, solvates and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound provided herein in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for treating neurological disorders in a subject in need thereof.
